Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 4/20 | 1.00 |
| ▸ | MMP2 | P08253 | 3/20 | 1.00 |
| ▸ | HTR2B | P41595 | 2/20 | 1.00 |
| ▸ | FNTA | P49354 | 1/20 | 0.78 |
| ▸ | FNTB | P49356 | 1/20 | 0.78 |
| ▸ | MEN1 | O00255 | 12/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 12/20 | 0.77 |
| ▸ | RECQL | P46063 | 8/20 | 0.77 |
| ▸ | MAPT | P10636 | 7/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.77 |
| ▸ | USP2 | O75604 | 5/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.77 |
| ▸ | TP53 | P04637 | 3/20 | 0.77 |
| ▸ | HBB | P68871 | 2/20 | 0.77 |
| ▸ | BLM | P54132 | 10/20 | 0.67 |
| ▸ | THRB | P10828 | 10/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.67 |
| ▸ | CASP1 | P29466 | 2/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.67 |
| ▸ | BRCA1 | P38398 | 5/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aclarubicin SCHEMBL2804048 | 1.00 | PTGS1 (1.00) | PTGS1MMP2HTR2BFNTAFNTB | |
| Aclarubicin SCHEMBL29390785 | 1.00 | PTGS1 (1.00) | PTGS1MMP2HTR2BFNTAFNTB | |
| Aclarubicin SCHEMBL31238004 | 1.00 | PTGS1 (1.00) | PTGS1MMP2HTR2BFNTAFNTB | |
| Aclarubicin SCHEMBL1649619 | 1.00 | PTGS1 (1.00) | PTGS1MMP2HTR2BFNTAFNTB | |
| Aclarubicin SCHEMBL10061856 | 1.00 | PTGS1 (1.00) | PTGS1MMP2HTR2BFNTAFNTB | |
| Aclarubicin SCHEMBL10079204 | 1.00 | PTGS1 (1.00) | PTGS1MMP2HTR2BFNTAFNTB | |
| Aclarubicin SCHEMBL17035568 | 1.00 | PTGS1 (1.00) | PTGS1MMP2HTR2BFNTAFNTB | |
| Aclarubicin SCHEMBL6255351 | 1.00 | PTGS1 (1.00) | PTGS1MMP2HTR2BFNTAFNTB | |
| Aclarubicin SCHEMBL31277372 | 1.00 | PTGS1 (1.00) | PTGS1MMP2HTR2BFNTAFNTB | |
| Aclarubicin SCHEMBL17167135 | 1.00 | PTGS1 (1.00) | PTGS1MMP2HTR2BFNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9353218-B2 | Kit for multifunctional compounds forming crosslinked biomaterials | ANGIOTECH PHARMACEUTICALS, INC. | 2016-05-31 | — | — | US | disclosed |
| US-9353218-B2 | Kit for multifunctional compounds forming crosslinked biomaterials | ANGIOTECH PHARMACEUTICALS, INC. | 2016-05-31 | — | — | US | disclosed |
| US-9326934-B2 | Drug delivery from rapid gelling polymer composition | ANGIOTECH INTERNATIONAL AG | 2016-05-03 | — | — | US | disclosed |
| US-9326934-B2 | Drug delivery from rapid gelling polymer composition | ANGIOTECH INTERNATIONAL AG | 2016-05-03 | — | — | US | disclosed |
| US-20130224276-A1 | COMPOSITIONS AND METHODS FOR COATING MEDICAL IMPLANTS | ANGIOTECH INTERNATIONAL AG (CH) | 2013-08-29 | — | — | US | disclosed |
| US-20130224276-A1 | COMPOSITIONS AND METHODS FOR COATING MEDICAL IMPLANTS | ANGIOTECH INTERNATIONAL AG (CH) | 2013-08-29 | — | — | US | disclosed |
| US-8486437-B2 | Multifunctional compounds for forming crosslinked biomaterials and methods of preparation and use | ANGIOTECH PHARMACEUTICALS (US), INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-8486437-B2 | Multifunctional compounds for forming crosslinked biomaterials and methods of preparation and use | ANGIOTECH PHARMACEUTICALS (US), INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-8481073-B2 | Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use | ANGIODEVICE INTERNATIONAL GMBH (CH) | 2013-07-09 | — | — | US | disclosed |
| US-8481073-B2 | Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use | ANGIODEVICE INTERNATIONAL GMBH (CH) | 2013-07-09 | — | — | US | disclosed |
| US-20070254833-A1 | Delivering a fibrosis inducing agent with a biopolymer or synthetic polymer, and optionally a hemostatic agent or antiseptic; nonsurgical, minimally invasive interventions | ANGIOTECH INTERNATIONAL AG (CH) | 2007-11-01 | — | — | US | disclosed |
| US-20070208134-A1 | Anti-scarring drug combinations and use thereof | HUNTER WILLIAM L | 2007-09-06 | — | — | US | disclosed |
| US-20070208134-A1 | Anti-scarring drug combinations and use thereof | HUNTER WILLIAM L | 2007-09-06 | — | — | US | disclosed |
| US-20070198063-A1 | Electrical devices and anti-scarring drug combinations | HUNTER WILLIAM L | 2007-08-23 | — | — | US | disclosed |
| US-20070198063-A1 | Electrical devices and anti-scarring drug combinations | HUNTER WILLIAM L | 2007-08-23 | — | — | US | disclosed |
| US-20070197957-A1 | Implantable sensors, implantable pumps and anti-scarring drug combinations | HUNTER WILLIAM L | 2007-08-23 | — | — | US | disclosed |
| US-20070197957-A1 | Implantable sensors, implantable pumps and anti-scarring drug combinations | HUNTER WILLIAM L | 2007-08-23 | — | — | US | disclosed |
| US-7241736-B2 | spider, silkworm or other silk as a fibrosing agent; induce adhesion or fibrosis in the walls of the diverticula or facilitate \"filling\" of the diverticula in situ; thus obliterating the lumen of the diverticula and relieving symptoms | ANGIOTECH INTERNATIONAL AG (CH) | 2007-07-10 | — | — | US | disclosed |
| US-7241736-B2 | spider, silkworm or other silk as a fibrosing agent; induce adhesion or fibrosis in the walls of the diverticula or facilitate \"filling\" of the diverticula in situ; thus obliterating the lumen of the diverticula and relieving symptoms | ANGIOTECH INTERNATIONAL AG (CH) | 2007-07-10 | — | — | US | disclosed |
| US-7166570-B2 | Treating varicose or veins by injecting a composition silk made of polyalkylene oxide-polyester block copolymer into the lumen of a vein; anchoring implantable medical devices into or onto biological tissue | ANGIOTECH INTERNATIONAL AG (CH) | 2007-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254833-A1 | Delivering a fibrosis inducing agent with a biopolymer or synthetic polymer, and optionally a hemostatic agent or antiseptic; nonsurgical, minimally invasive interventions | MMP1, COL1A1, SERPINC1 | PTGS1 146/4885MMP2 65/4885HTR2B 4201/4885 |
| US-20070208134-A1 | Anti-scarring drug combinations and use thereof | MMP1, COL2A1, COL1A1 | PTGS1 72/4885MMP2 88/4885HTR2B 2883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.